Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Clinical trial NCT06898957 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06898957
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-16
- Primary completion
- 2031-06-23
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.